News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
This is the company’s first partnership arrangement in China
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
The drug is priced at Rs 2000 for a course of 40 tablets
This product will be manufactured at Lupin's Goa facility in India
FDA changes inspection classification of the facility to Voluntary Action Indicated
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Subscribe To Our Newsletter & Stay Updated
